European Inter-Institutional Impact Study of MammaPrint

Publication Name: The Breast

Author(s): P.G. Cusumano, D. Generali, E. Ciruelos, L. Manso, I. Ghanem, E. Lifrange, G. Jerusalem, J. Klaase, F. de Snoo, L. Stork-Sloots, L. Dekker-Vroling, M. Lutke Holzik

Aim To measure the impact of MammaPrint on adjuvant treatment decisions and to analyze the agreement in treatment decisions between hospitals from 4 European countries for the same patient cohort. Methods Breast cancer patients were prospectively enrolled and MammaPrint was … Continued

Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature.

Publication Name: European Journal of Cancer

Author(s): Drukker CA, van den Hout HC, Sonke GS, Brain E, Bonnefoi H, Cardoso F, Goldhirsch A, Harbeck N, Honkoop AH, Koornstra RHT, van Laarhoven HWM, Portielje JEA, Schneeweiss A, Smorenburg CH, Stouthard J, Linn SC, Schmidt MK

BACKGROUND: Clinical decision-making in patients with early stage breast cancer requires adequate risk estimation by medical oncologists. This survey evaluates the agreement among oncologists on risk estimations and adjuvant systemic treatment (AST) decisions and the impact of adding the 70-gene … Continued

Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer

Publication Name: International Journal of Molecular Medicine

Author(s): Heidrun Gevensleben, Uwe-Jochen Gohring, Reinhard Buttner. Lukas C. Heukamp, Georg Kunz, Thomas Dimpfl, Christian Jackisch, Olaf Ortmann, Ute-Susann Albert, Richard Bender, Femke De Snoo, Oscar Krijgsman, Annuska M. Glas

The 70-gene expression profile MammaPrint is a powerful prognostic indicator for disease outcome in breast cancer patients with improved prediction of recurrence risk compared to currently used guidelines. The microarray-based test TargetPrint further provides reliable, quantitative assessment of mRNA expression … Continued